Latest Report Of China Myasthenia Gravis Therapeutics Market Growth, Opportunities, Risk, Challenges, Gross Margin, Covid-19 Outbreaks

Report Overview

The China Myasthenia Gravis Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 8.2% during the forecast period.

Myasthenia gravis (MG) is an organ-specific autoimmune disorder of the neuromuscular junction, characterized by specific autoantibodies against skeletal muscular antigens in the postsynaptic membrane. And 85% of all patients experience generalized myasthenia gravis affecting proximal muscles of the extremities and the trunk. The annual incidence of myasthenia gravis in China is 29400 and the prevalence is 165600 in 2019. China has a large number of patients (650,000) who are suffering from MG disease. The admission mortality rate was 14.69%. Most cases of new onset MG occurred in the seventh decade of life. In China, the incidence rate of myasthenic crisis (4.81%) and mortality rate (6.4%) are less as compared to the USA.

Market Drivers

The market is majorly driven by the rising geriatric population (12.57% by end of 2019). The mean age of disease diagnosis was 52.2 years, with adults 55.9 years and children 8.9 years. Key factorsthat aredrivingthemarket growthinclude rising adoption of immunotherapies, approval of promising drugs, emergence of biologics, increase in incidence (annually in China 29400) and increasing awareness of rare diseases.

However, the side effects caused by several therapeutics are restraining market growth. Some of the products are withdrawn from the market due to serious side effects. In April 2019, high dose combination of Cholinesterase Inhibitors (ChEIs) and Calcineurine Inhibitors (CNIs) such as Mestinon and Prograf are responsible for severe muscle cramps in myasthenia gravis patients. High cost of treatment also impacts the growth of the market.

Get Exclusive Free Sample Report @ https://www.prudentmarkets.com/sample-request/139787/

Major Players

Some of key players in the myasthenia gravis therapeutics market are Alexion Pharmaceuticals, Inc.; Harbour BioMed; HanAll Biopharma; Shanghai Zhongxi Sanwei Pharmaceutical Co., Ltd.; Pfizer Inc.; F. Hoffmann-La Roche AG; argenx SE; Zai Lab Limited; RemeGen Co., Ltd; Novartis AG; UCB Pharma;

Many new players are emerging in the myasthenia gravis therapeutics market, as a result of a number of growth opportunities. Key players adopting various strategies such as partnership, licensing agreement. For instance, licensing agreement between HanAll Biopharma-Harbour BioMed's Batoclimab (HBM9161) receives China CDE breakthrough therapy designation for treatment of adult patients with Myasthenia Gravis. And some universities in China are also developing drugs for MG disease (Sun Yat-Sen University in China is conducting phase III clinical trial of Azathioprine and Leflunomide for treatment of myasthenia gravis).

argenx and Zai Lab announce Strategic Collaboration for Efgartigimod in Greater China. Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China, Efgartigimod is an investigational antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) antibodies and block the IgG recycling process.

The report delivers the challenges in front of the China Myasthenia Gravis Therapeutics Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the China Myasthenia Gravis Therapeuticss Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On China Myasthenia Gravis Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139787/

Market Segmentation

By Drug Type:

On the basis of drug type, the China Myasthenia Gravis therapeutics market can be segmented into cholinesterase inhibitors and immunosuppressive drugs.

Cholinesterase inhibitors include Pyridostigmine bromide and in China maximum oral dose per day is 480 mg 3 to 4 times. Immunosuppressive drugs consist of such as Glucocorticoids (Prednisone, Methylprednisolone and Dexamethasone), Azathioprine, Cyclosporin A, Tacrolimus (FK-506), Cyclophosphamide, Mycophenolate Mofetil (MMF), Rituximab.

By Surgery:

On the basis of surgery, the China Myasthenia Gravis therapeutics market can be segmented into Thymectomy. Thymectomy is one of the main treatment methods for myasthenia gravis. It is a surgical procedure where the thymus gland is removed to stop the production of autoantibodies that mistakenly attack the muscle-nerve connections in myasthenia gravis patients.

By Region:

On the basis of region, the China Myasthenia Gravis therapeutics market is segmented into coastal and inland regions. The estimated incidence of myasthenia gravis per 100,000 persons-years varied from 0.10 Tibet to 1.17 in Beijing.  The incidence of myasthenia gravis was higher in Coastal areas than that in the Inland areas, especially in Bohai sea zone including Liaoning, Beijing, Hebei, and Shandong provinces. The estimated prevalence of myasthenia gravis is 5.09 in Henan province, 6.47 in Hubei province, and 2.19-11.07 per 100,000 in Guangzhou city.

Fig- Incidence rates of Myasthenia Gravis for 31 provinces and administrative division in mainland China. (According to THE LANCET regional health report published in 2020).

Major Players

Some of key players in the myasthenia gravis therapeutics market are Alexion Pharmaceuticals, Inc.; Harbour BioMed; HanAll Biopharma; Shanghai Zhongxi Sanwei Pharmaceutical Co., Ltd.; Pfizer Inc.; F. Hoffmann-La Roche AG; argenx SE; Zai Lab Limited; RemeGen Co., Ltd; Novartis AG; UCB Pharma;

Many new players are emerging in the myasthenia gravis therapeutics market, as a result of a number of growth opportunities. Key players adopting various strategies such as partnership, licensing agreement. For instance, licensing agreement between HanAll Biopharma-Harbour BioMed's Batoclimab (HBM9161) receives China CDE breakthrough therapy designation for treatment of adult patients with Myasthenia Gravis. And some universities in China are also developing drugs for MG disease (Sun Yat-Sen University in China is conducting phase III clinical trial of Azathioprine and Leflunomide for treatment of myasthenia gravis).

argenx and Zai Lab announce Strategic Collaboration for Efgartigimod in Greater China. Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China, Efgartigimod is an investigational antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) antibodies and block the IgG recycling process.

The China Myasthenia Gravis Therapeutics Market report is an easy-to-understand giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the China Myasthenia Gravis Therapeutics market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the China Myasthenia Gravis Therapeutics Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic China Myasthenia Gravis Therapeutics market. Each section of the research study is specially prepared to explore key aspects of the global China Myasthenia Gravis Therapeutics Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global China Myasthenia Gravis Therapeutics market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]: https://www.prudentmarkets.com/discount-request/139787/

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global China Myasthenia Gravis Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the China Myasthenia Gravis Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the China Myasthenia Gravis Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the China Myasthenia Gravis Therapeutics
Chapter 4: Presenting the China Myasthenia Gravis Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the China Myasthenia Gravis Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business: https://www.prudentmarkets.com/enquiry-request/139787/

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.